Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective

Yang Yang, Md Sahidul Islam, Jin Wang, Yuan Li, Xin Chen, Yang Yang, Md Sahidul Islam, Jin Wang, Yuan Li, Xin Chen

Abstract

Currently, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV, the causative pathogen of Coronavirus Disease 2019 (COVID-19)) has rapidly spread across China and around the world, causing an outbreak of acute infectious pneumonia. No specific anti-virus drugs or vaccines are available for the treatment of this sudden and lethal disease. The supportive care and non-specific treatment to ameliorate the symptoms of the patient are the only options currently. At the top of these conventional therapies, greater than 85% of SARS-CoV-2 infected patients in China are receiving Traditional Chinese Medicine (TCM) treatment. In this article, relevant published literatures are thoroughly reviewed and current applications of TCM in the treatment of COVID-19 patients are analyzed. Due to the homology in epidemiology, genomics, and pathogenesis of the SARS-CoV-2 and SARS-CoV, and the widely use of TCM in the treatment of SARS-CoV, the clinical evidence showing the beneficial effect of TCM in the treatment of patients with SARS coronaviral infections are discussed. Current experiment studies that provide an insight into the mechanism underlying the therapeutic effect of TCM, and those studies identified novel naturally occurring compounds with anti-coronaviral activity are also introduced.

Keywords: SARS-CoV-2; Traditional Chinese Medicine (TCM); coronavirus pneumonia.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

© The author(s).

References

    1. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020. 12.
    1. Burki TK. Coronavirus in China. Lancet Respir Med. 2020.
    1. World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. . 2020.
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020. 2020. 02.06.20020974.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
    1. World Health Organization. Situation Report-29. . 2020.
    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
    1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020.
    1. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020.
    1. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327–47.
    1. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology. 2020: 200343.
    1. Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Nat Rev Drug Discov. 2020.
    1. Liu J, Manheimer E, Shi Y, Gluud C. Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis. J Altern Complement Med. 2004;10:1041–51.
    1. Li T, Peng T. Traditional Chinese herbal medicine as a source of molecules with antiviral activity. Antiviral Res. 2013;97:1–9.
    1. Leung PC. The efficacy of Chinese medicine for SARS: a review of Chinese publications after the crisis. Am J Chin Med. 2007;35:575–81.
    1. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP. et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Mil Med Res. 2020;7:4.
    1. Habibzadeh P, Stoneman EK. The Novel Coronavirus: A Bird's Eye View. Int J Occup Environ Med. 2020;11:65–71.
    1. Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother. 2018;26:2040206618764483.
    1. De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chem Asian J. 2019;14:3962–8.
    1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020.
    1. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017. 9.
    1. Zhang L, Liu Y. Potential Interventions for Novel Coronavirus in China: A Systemic Review. J Med Virol. 2020.
    1. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020.
    1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020: 105924.
    1. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6:67–9.
    1. Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y. et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23:300–2.
    1. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immuno. 2004;136:95–103.
    1. He L, Ding Y, Zhang Q, Che X, He Y, Shen H. et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006;210:288–97.
    1. Faure E, Poissy J, Goffard A, Fournier C, Kipnis E, Titecat M. et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One. 2014;9:e88716.
    1. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP. et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19:1313–7.
    1. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343.
    1. Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019;2:Cd010406.
    1. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA. et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018;197:757–67.
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020.
    1. World Health Organization. . 2020.
    1. Hung IFN, To KKW, Lee CK, Lee KL, Yan WW, Chan K. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144:464–73.
    1. Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs. Chin J Integr Med. 2020.
    1. Tong X, Li A, Zhang Z, Duan J, Chen X, Hua C. et al. TCM treatment of infectious atypical pneumonia-a report of 16 cases. J Tradit Chin Med. 2004;24:266–9.
    1. Liu X, Zhang M, He L, Li Y. Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS) Cochrane Database Syst Rev. 2012;10:Cd004882.
    1. Zhang MM, Liu XM, He L. Effect of integrated traditional Chinese and Western medicine on SARS: a review of clinical evidence. World J Gastroenterol. 2004;10:3500–5.
    1. Zhong N, May RM, McLean AR, Pattison J, Weiss RA. Management and prevention of SARS in China. Philos Trans R Soc Lond B Biol Sci. 2004;359:1115–6.
    1. JSM P, D P, Yuen KY ea. The Severe Acute Respiratory Syndrome. New Engl J Med. 2003;249:2431–41.
    1. Jr TMF, Tsang KWT. Severe Acute Respiratory Syndrome. Nat Med. 2005;4:95–106.
    1. Chen Z, Nakamura T. Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS. Phytotherapy research: PTR. 2004;18:592–4.
    1. T.F. Lau, Leung PC, Wong ELY, Fong C, Cheng KF, Zhang SC, et al. Using Herbal Medicine as a Means of Prevention Experience During the SARS Crisis. Am J Chin Med. 2005;33:345–56.
    1. Poon PM, Wong CK, Fung KP, Fong CY, Wong EL, Lau JT. et al. Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study. Am J Chin Med. 2006;34:13–21.
    1. Hsu CH, Hwang KC, Chao CL, Chang SG, Ho MS, Chou P. Can herbal medicine assist against avian flu? Learning from the experience of using supplementary treatment with Chinese medicine on SARS or SARS-like infectious disease in 2003. J Altern Complement Med. 2006;12:505–6.
    1. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. The Lancet. 2003;361:2045–6.
    1. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW. et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31:69–75.
    1. Wang SQ, Du QS, Zhao K, Li AX, Wei DQ, Chou KC. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. Amino Acids. 2007;33:129–35.
    1. Wu T, Yang X, Zeng X, Poole P. Traditional Chinese medicine in the treatment of acute respiratory tract infections. Resp Med. 2008;102:1093–8.
    1. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochimica et biophysica acta. 2013;1830:3670–95.
    1. Luo W, Su X, Gong S, Qin Y, Liu W, Li J, Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts. BioScience Trends. 2009. 3.
    1. Fung KP, Leung PC, Tsui KW, Wan CC, Wong KB, Waye MY. et al. Immunomodulatory activities of the herbal formula Kwan Du Bu Fei Dang in healthy subjects: a randomised, double-blind, placebo-controlled study. Hong Kong Med J. 2011;17(Suppl 2):41–3.
    1. Lau KM, Lee KM, Koon CM, Cheung CS, Lau CP, Ho HM. et al. Immunomodulatory and anti-SARS activities of Houttuynia cordata. J Ethnopharmacol. 2008;118:79–85.
    1. Gong SJ, Su XJ, Yu HP, Li J, Qin YJ, Xu Q. et al. A study on anti-SARS-CoV 3CL protein of flavonoids from litchi chinensis sonn core. Chinese Pharmacological Bulletin. 2008;24:699–700.
    1. Lin CW, Tsai FJ, Tsai CH, Lai CC, Wan L, Ho TY. et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005;68:36–42.
    1. Nguyen TTH, Woo HJ, Kang HK, Nguyen VD, Kim YM, Kim DW. et al. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnol Lett. 2012;34:831–8.
    1. Jo S, Kim S, Shin DH, Kim M-S. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020;35:145–51.
    1. Jo S, Kim H, Kim S, Shin DH, Kim MS. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Chem Biol Drug Des. 2019.
    1. Yu MS, Lee J, Lee JM, Kim Y, Chin YW, Jee JG. et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg Med Chem Lett. 2012;22:4049–54.
    1. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YSE. et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101:10012–7.
    1. Kuhn JH, Radoshitzky SR, Li W, Wong SK, Choe H, Farzan M. The SARS Coronavirus receptor ACE 2 A potential target for antiviral therapy. In: Holzenburg A, Bogner E, editors. New Concepts of Antiviral Therapy. Boston, MA: Springer US. 2006. p. 397-418.
    1. Letko M, Munster V. Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. bioRxiv. 2020. 2020. 01.22.915660.
    1. Lin HX, Feng Y, Wong G, Wang L, Li B, Zhao X. et al. Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction. J Gen Virol. 2008;89:1015–24.
    1. Xu XT, Chen P, Wang JF, Feng JN, Zhou H, Li X, Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020.
    1. Ho T, Wu S, Chen J, Li C, Hsiang C. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74:92–101.
    1. Deng YF, Aluko RE, Jin Q, Zhang Y, Yuan LJ. Inhibitory activities of baicalin against renin and angiotensin-converting enzyme. Pharm Biol. 2012;50:401–6.
    1. Takahashi S, Yoshiya T, Yoshizawa-Kumagaye K, Sugiyama T. Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. Biomed Res. 2015;36:219–24.
    1. Wang W, Ma X, Han J, Zhou M, Ren H, Pan Q. et al. Neuroprotective Effect of Scutellarin on Ischemic Cerebral Injury by Down-Regulating the Expression of Angiotensin-Converting Enzyme and AT1 Receptor. PLoS One. 2016;11:e0146197.
    1. Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G. et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol. 2004;78:11334–9.
    1. Schwarz S, Wang K, Yu WJ, Sun B, Schwarz W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral res. 2011;90:64–9.
    1. Schwarz S, Sauter D, Wang K, Zhang R, Sun B, Karioti A. et al. Kaempferol Derivatives as Antiviral Drugs against the 3a Channel Protein of Coronavirus. Planta Medica. 2014;80:177–82.
    1. Cheng PW, Ng LT, Chiang LC, Lin CC. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin Exp Pharmacol Physiol. 2006;33:612–6.
    1. Pilcher H. Liquorice may tackle SARS. Nature. 2003.
    1. Chen CJ, Michaelis M, Hsu HK, Tsai CC, Yang KD, Wu YC. et al. Toona sinensis Roem tender leaf extract inhibits SARS coronavirus replication. J Ethnopharmacol. 2008;120:108–11.
    1. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Biosci Trends. 2020.
    1. Science CAo. Researchers in Shanghai Institute of Drugs and Wuhan Virus Institute discovered that the Chinese patent medicine Shuanghuanglian oral liquid can inhibit the 2019-new coronavirus.; 2020.
    1. Chen X, Howard OM, Yang X, Wang L, Oppenheim JJ, Krakauer T. Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function. Life Sci. 2002;70:2897–913.
    1. Gao Y, Fang L, Cai R, Zong C, Chen X, Lu J. et al. Shuang-Huang-Lian exerts anti-inflammatory and anti-oxidative activities in lipopolysaccharide-stimulated murine alveolar macrophages. Phytomedicine. 2014;21:461–9.
    1. Chan MC, Chan RW, Mok CK, Mak NK, Wong RN. Indirubin-3'-oxime as an antiviral and immunomodulatory agent in treatment of severe human influenza virus infection. Hong Kong Med J. 2018;24(Suppl 6):45–7.
    1. Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q. et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017;17:130.
    1. Dong L, Xia JW, Gong Y, Chen Z, Yang H-H, Zhang J. et al. Effect of Lianhuaqingwen Capsules on Airway Inflammation in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Evid Based Complement Alternat Med. 2014;2014:1–11.
    1. Li S, Chen C, Zhang H, Guo H, Wang H, Wang L. et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res. 2005;67:18–23.
    1. Chang FR, Yen CT, Ei-Shazly M, Lin WH, Yen MH, Lin KH. et al. Anti-Human Coronavirus (anti-HCoV) Triterpenoids from the Leaves of Euphorbia Neriifolia. Nat Prod Commun. 2012;7:1934578X1200701103.
    1. Shen YC, Wang LT, Khalil AT, Chiang LC, Cheng PW. Bioactive Pyranoxanthones from the Roots of Calophyllum blancoi. Chem Pharm Bull. 2005;53:244–7.
    1. National Health Commission of the People's Republic of China. Transcript of press conference in 17, February, 2020. . shtml. 2020.
    1. National Health Commission of the People's Republic of China. Notice on the issunance of guidelines of diagnosis and treatment for 2019-nCoV infected pneumonia (version 6) 6 ed; . 2020.
    1. Han YY, Zhao MR, Shi B, Song ZH, Zhou SP, He Y. Application of integrative medicine protocols on treatment of coronavirus disease 2019. Chi Tradit Herbal Drugs. 1-5.
    1. Zhu YG, Deng ZW, Liu LH, Liu XH, Li XZ, Chen WH, Compilation of drug information for the diagnosis and treatment of COVID-19 (version 1) Central South Pharmacy. 1-14.
    1. Xu X, Zhang Y, Li X, Li XX. Analysis on prevention plan of corona virus disease-19 (COVID-19) by traditional Chinese medicine in various regions. Chin Herb Med. 2020. pp. 1–7.
    1. Zhao J, Tian SS, Yang J, Liu J, Zhang WD. Investigating the mechanism of Qing-Fei-Pai-Du-Tang for the treatment of Novel Coronavirus Pneumonia by network pharmacology. Chin Herb Med. 2020. pp. 1–7.
    1. Yao KT, Liu MY, Li X, Huang JH, Cai HB. Retrospective Clinical Analysis on Treatment of Novel Coronavirus-infected Pneumonia with Traditional Chinese Medicine Lianhua Qingwen. Chin J Exp Tradit Med Form. 2020. pp. 1–7.
    1. Lv RB, Wang WJ, Li X. Treatment of suspected new coronavirus pneumonia with Chinese medicine Lianhua Qingwen Clinical observation of 63 suspected cases. J Tradit Chin Med. 2020. pp. 1–5.
    1. Zhang JW, Hu X, Jin PF. Cytokine storms caused by 2019-nCoV and drug therapy. Chinese Pharmaceutical Journal. 2020. pp. 1–9. 96.
    1. Chen X, Yang D, Shen W, Dong HF, Wang JM, Oppenheim JJ. et al. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm Res. 2000;49:744–55.
    1. Chen X, Mellon RD, Yang L, Dong H, Oppenheim JJ, Howard OM. Regulatory effects of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine Niuhuang, on human leukocyte response to chemoattractants. Biochem Pharmacol. 2002;63:533–41.
    1. Chen X, Beutler JA, McCloud TG, Loehfelm A, Yang L, Dong HF. et al. Tannic acid is an inhibitor of CXCL12 (SDF-1alpha)/CXCR4 with antiangiogenic activity. Clin Cancer Res. 2003;9:3115–23.
    1. Chen X, Yang L, Zhang N, Turpin JA, Buckheit RW, Osterling C. et al. Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2003;47:2810–6.
    1. Chen X, Oppenheim JJ, Howard OM. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components. Cell Mol Immunol. 2004;1:336–42.
    1. Chen X, Murakami T, Oppenheim JJ, Howard OM. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood. 2005;106:2409–16.
    1. He J, He ZD, Chen X. Effects of Chinese medicinal components on chemokine receptors: theory, results and methodology. Evidence-based Research Methods for Chinese Medicine. 2016. pp. 187–97.
    1. Chen YB, Chen X. Ancient herbal component may be a novel therapeutic for gouty arthritis. J Leukoc Biol. 2019;105:7–9.
    1. Wang J, Qiao LF, Li YS, Yang GT. Shen Fu injection activate the macrophage NF-kB of rats' alveolar induced by LPS. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong. 2009;1:15–8.
    1. Chang XJ, Xiao W, Zhang S, Chang YP, Chen CM, Chen J. et al. Mechanism of Re Du Ning injection on anti-acute lung injury in rats based on cytokines storm. Chin Herb Med. 2014;46:236–9.
    1. Zou HM, He TZ, Chen X. Tetrandrine inhibits differentiation of proinflammatory subsets of T helper cells but spares de novo differentiation of iTreg cells. Int Immunopharmacol. 2019;69:307–12.
    1. Chen H, Du Q. Potential Natural Compounds for Preventing 2019-nCoV Infection. Preprints. 2020.
    1. Ng AWT, Poon SL, Huang MN, Lim JQ, Boot A, Yu W, Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci Trans Med. 2017. 9.
    1. Zeng ZP, Jiang JG. Analysis of the adverse reactions induced by natural product-derived drugs. Br J Pharmacol. 2010;159:1374–91.
    1. Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355:134–8.
    1. Liu LS, Lei N, Lin Q, Wang WL, Yan HW, Duan XH. The Effects and Mechanism of Yinqiao Powder on Upper Respiratory Tract Infection. Int J Biotechnol Wellness Ind. 2015;4:57–60.
    1. Fu YJ, Yan YQ, Qin HQ, Wu S, Shi SS, Zheng X. et al. Effects of different principles of Traditional Chinese Medicine treatment on TLR7/NF-κB signaling pathway in influenza virus infected mice. Chin Med. 2018;13:42.
    1. Lau JT, Leung PC, Wong EL, Fong C, Cheng KF, Zhang SC. et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. J Altern Complement Med. 2005;11:49–55.
    1. Du CY, Zheng KY, Bi CW, Dong TT, Lin H, Tsim KW. Yu Ping Feng San, an Ancient Chinese Herbal Decoction, Induces Gene Expression of Anti-viral Proteins and Inhibits Neuraminidase Activity. Phytother Res. 2015;29:656–61.
    1. Gao J, Li J, Shao X, Jin Y, Lu XW, Ge JF. et al. Antiinflammatory and immunoregulatory effects of total glucosides of Yupingfeng powder. Chin Med J (Engl) 2009;122:1636–41.
    1. Zhang H, Chen Q, Zhou W, Gao S, Lin H, Ye S. et al. Chinese medicine injection shuanghuanglian for treatment of acute upper respiratory tract infection: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med. 2013;2013:987326.
    1. Xiao GL, Song K, Yuan CJ ea. A literature report on the treatment of SARS by stages with traditional Chinese medicine. J Emerg Chin Med Hunan. 2005. pp. 53–5.
    1. Bao L, J M. Research progress of Da Yuan Yin on the treatment of infectious diseases. Emerg Tradit Chin Med. 2010;2:263–87.
    1. Kim DE, Min JS, Jang MS, Lee JY, Shin YS, Song JH. et al. Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells. Biomolecules. 2019;9:696.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit